Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. - Wikidata - awgldk - TriplyDB

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

http://www.wikidata.org/entity/Q54589517

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment Individualising treatment choices in a crowded treatment algorithm Circulating biomarkers in advanced renal cell carcinoma: clinical applications Predictive markers of efficacy for an angiopoietin-2 targeting therapeutic in xenograft models Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma Renal cancer biomarkers: the promise of personalized care A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk Biomarkers for anti-angiogenic therapy in cancer.Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).Concise drug review: pazopanib and axitinib.Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.Biomarkers for tyrosine kinase inhibitors in renal cell cancer.The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.Pazopanib for the treatment of breast cancer.Cardiovascular medications in angiogenesis--how to avoid the sting in the tail.Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.Second-line systemic therapy for the treatment of metastatic renal cell cancer.Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma.Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.Optimal management of metastatic renal cell carcinoma: current status.

P2860

Q24606852-FDA3B974-2DBC-4985-9C2D-75A65598CD13 Q26779144-20E4BD27-1EB2-469A-9B1E-153B4425E1F5 Q26996793-CFD70919-0C81-472F-A94F-C9375E9D41D4 Q27023669-400DC889-BFDB-4F4D-B52B-49024B1F0401 Q27023770-3A695AE8-D240-4F18-8CDD-CE08C5C4DA4A Q27302122-3E468464-D281-435A-A3E4-CF73FB46A30E Q28067482-E79BC200-6B31-475E-B842-C5D3BD85B70E Q33409364-13F0A6F1-8863-4857-8862-8D56A61682AD Q33425137-1325F5D5-382E-4AD1-B10C-728E72E4EE86 Q33426958-C6861DB3-5A75-48AC-B8CF-8BAB4077245C Q34243444-75F0FD4E-0A61-49A3-A31C-DBB4A00660BB Q34422845-F55FAEF7-4A2A-4012-91AE-28CCD0654C6E Q34500117-D8E0017C-0148-4881-AD53-DB208AFBB6EC Q34695003-A14221D2-12C3-479A-82DC-62C6400E47FD Q35212949-6FEEFF16-ED61-4ABF-9895-56C67A0C414E Q35274936-E6E11BAC-9719-408D-AFD9-18DA2FADF2B1 Q35534962-806AB947-170D-4F06-B335-0C5B0DA79394 Q35607787-D70FE011-4D88-4FFE-B991-460C22D32734 Q35758408-5FF08FA8-E954-4FBB-9343-CD418F5F061F Q35776264-92747E16-B965-472C-AC47-7BE1FFDE005E Q36182836-716A7BBE-815D-4072-B16A-CF501D3B581B Q36275134-7756A7FF-12DC-43AF-9E8C-6DAEED8E9860 Q36413467-B13C8356-5F38-47CE-A3D6-DB7BCB8CACD5 Q36450612-4E1DDC6E-BCD7-4F6A-A1F6-E359BAACA19B Q36528151-3C99D757-D01C-4771-8DB3-7BADA72D47E8 Q36615090-5B06603F-4A47-4082-BB56-73453A9464A4 Q36663566-E8502022-AFA2-4DA4-8D43-2CF6BA65BC7C Q36893510-66FDD3CC-1B6F-4F0F-8E42-F3A1BFAD8F1B Q37081930-A30C4595-7512-410B-B2D5-4173EAED6C9E Q37437235-28E1C0B8-635B-4951-B304-A1E54C97E332 Q37470058-51578559-4382-4867-AD5E-A9E1B4C2A0D9 Q37910970-55EC77CE-66E0-439D-94E1-A826F4773E54 Q37974693-BE7118D3-69AB-442E-8125-A5014CCEB4C0 Q38001305-381F4445-D982-4895-8057-80CE226B26B1 Q38012779-0B97A012-D58F-40CE-9FB0-AA219717C696 Q38020244-2CF9764C-C8F5-41F5-94D4-8DEC25A8DEE8 Q38022052-DD64E01F-E9C3-402C-BE1F-284DEBC8F37C Q38040684-9A8A9A6A-DE1F-406E-8A1A-DDE3279B2C26 Q38059507-5395EEBC-5AC3-4891-A497-140DB2624E92 Q38097746-D27F2B1A-1549-4940-BBF0-4125A09DDF8D

P2860

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

http://www.wikidata.org/entity/Q54589517

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Pazopanib efficacy in renal ce ...... ed and exposure-related genes.

@en

Pazopanib efficacy in renal ce ...... ed and exposure-related genes.

@nl

type

label

Pazopanib efficacy in renal ce ...... ed and exposure-related genes.

@en

Pazopanib efficacy in renal ce ...... ed and exposure-related genes.

@nl

prefLabel

Pazopanib efficacy in renal ce ...... ed and exposure-related genes.

@en

Pazopanib efficacy in renal ce ...... ed and exposure-related genes.

@nl

P1433

Q54589517-175FF06A-2646-40EA-8B14-3954FFC9C127

P1476

Q54589517-D3393035-497A-464D-92BC-A0BF44FABEFD

P2093

Q54589517-2320701C-7D00-47C6-B7C4-3ECD98EAC536

Q54589517-297365C0-05DE-4269-ACD7-5FD04E03C140

Q54589517-2F8BF598-F5D5-4329-8B43-26C18B9748D6

Q54589517-32D44701-52CC-4EFA-9569-99F47F099AA2

Q54589517-402D8991-D4D6-471B-93A5-877D6D5DA4E3

Q54589517-4BABA2E6-C1C1-4BEF-BCA3-2B9460FA4C9F

Q54589517-50571B26-6BAA-487C-A06C-C9AE8FB36F69

Q54589517-71EC64FE-1FFC-4F0A-AD90-597C0FC79B7E

Q54589517-77F93378-8713-41EE-AA14-F9346A528262

Q54589517-94BE78AF-5F4E-47B8-B275-F98598349621

P304

Q54589517-7D100EF5-4E92-4634-AAF2-27B796A5893A

P31

Q54589517-0C37D442-F186-40C1-AD58-987BA261B286

P356

Q54589517-08AE82F2-9CF2-4271-8C00-A7FA75EE4838

P407

Q54589517-8821CB75-FD99-4EA1-9A01-12DBEA1EE7DD

P433

Q54589517-BDC5E0F7-E084-48B5-9FEE-A0763FAC6F3C

P478

Q54589517-21CA659F-EB95-4C31-8458-EABFC4586C8B

P50

Q54589517-35E73D8E-8A76-414D-AD15-6862FE01C2BA

Q54589517-F55F9265-4DC0-45D3-977A-E82DCE2A90BF

P577

Q54589517-5B710B91-0822-4264-A828-403ADC504788

P698

Q54589517-5510C6A5-D5B4-49F3-9B9F-BB6D34087663

P356

JCO.2010.32.9110

P1433

Journal of Clinical Oncology

P1476

Pazopanib efficacy in renal ce ...... ted and exposure-related genes

@en

P2093

Colin F Spraggs

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Dilip Rajagopalan

http://www.w3.org/2001/XMLSchema#string

Howard A Ball

http://www.w3.org/2001/XMLSchema#string

Karen S King

http://www.w3.org/2001/XMLSchema#string

Lauren McCann

http://www.w3.org/2001/XMLSchema#string

Leigh J Ragone

http://www.w3.org/2001/XMLSchema#string

Lini N Pandite

http://www.w3.org/2001/XMLSchema#string

Lon R Cardon

http://www.w3.org/2001/XMLSchema#string

Nan X Bing

http://www.w3.org/2001/XMLSchema#string

P304

2557-2564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.9110

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21576632

http://www.w3.org/2001/XMLSchema#string